MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

MDT

87.11

-0.93%↓

A

115.09

-0.3%↓

VEEV

151.46

-3.57%↓

HQY

78.12

-6.83%↓

TLRY

6.58

-1.94%↓

Search

Simulations Plus Inc

Slēgts

SektorsVeselības aprūpe

13.12 1.47

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

12.56

Max

14.93

Galvenie mērījumi

By Trading Economics

Ienākumi

1.4M

676K

Pārdošana

961K

18M

Dividenžu ienesīgums

0.48

Peļņas marža

3.67

Darbinieki

212

EBITDA

-3M

2.3M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt

Prognoze 12 mēnešiem

+80.91% upside

Dividendes

By Dow Jones

Dividenžu ienesīgums

Sektora vidējais

0.48%

2.36%

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-117M

251M

Iepriekšējā atvēršanas cena

11.65

Iepriekšējā slēgšanas cena

13.12

Ziņu noskaņojums

By Acuity

40%

60%

150 / 348 Rangs Healthcare

Simulations Plus Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 10. apr. 17:04 UTC

Galvenie tirgus virzītāji

FDA Rejects Replimune's Melanoma Drug for a Second Time

2026. g. 11. apr. 00:00 UTC

Peļņas
Iegādes, apvienošanās, pārņemšana

Big Yachts, Big Bucks -- Barrons.com

2026. g. 10. apr. 21:55 UTC

Iegādes, apvienošanās, pārņemšana

Paramount Warrants Are an Underappreciated Aspect of Warner Bros. Deal -- Barrons.com

2026. g. 10. apr. 21:01 UTC

Peļņas

Cango Inc.: Files Annual Report on Form 20-F With SEC

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Energy & Utilities Roundup: Market Talk

2026. g. 10. apr. 20:50 UTC

Tirgus saruna
Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 10. apr. 20:50 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. apr. 20:31 UTC

Tirgus saruna

Convenience Store Traffic Slows as Gas Prices Rise -- Market Talk

2026. g. 10. apr. 20:10 UTC

Iegādes, apvienošanās, pārņemšana

This Women's Health Company Is Drawing Takeover Interest. The Stock Is Soaring. -- Barrons.com

2026. g. 10. apr. 19:15 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 10. apr. 19:15 UTC

Tirgus saruna

Oil Futures Settle Lower With Focus on U.S.-Iran Talks -- Market Talk

2026. g. 10. apr. 19:08 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2026. g. 10. apr. 19:08 UTC

Tirgus saruna

U.S. Natural Gas Futures End Week Lower -- Market Talk

2026. g. 10. apr. 18:38 UTC

Tirgus saruna

Canada's Job Market Showing Soft Demand, Structural Decline in Supply -- Market Talk

2026. g. 10. apr. 18:25 UTC

Tirgus saruna
Galvenie ziņu notikumi

Precious Metals Finish With Weekly Gains -- Market Talk

2026. g. 10. apr. 18:05 UTC

Tirgus saruna

Rising Commodity Prices Seen Carrying More Weight Than Jobs Data for Bank of Canada Watchers -- Market Talk

2026. g. 10. apr. 17:31 UTC

Tirgus saruna
Galvenie ziņu notikumi

U.S. Oil Rig Count Unchanged This Week At 411 -- Market Talk

2026. g. 10. apr. 17:26 UTC

Peļņas

Big Banks' Profits Set to Rise Even as 'Wall of Worry' Looms -- Barrons.com

2026. g. 10. apr. 17:10 UTC

Tirgus saruna

White House Defense of Stablecoin Yields Is Welcome Move, Grayscale Says -- Market Talk

2026. g. 10. apr. 17:00 UTC

Galvenie ziņu notikumi

Construction Business Taking a Hit From Iran Conflict -- WSJ

2026. g. 10. apr. 16:20 UTC

Tirgus saruna

Health Care Roundup: Market Talk

2026. g. 10. apr. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2026. g. 10. apr. 16:12 UTC

Peļņas

Partners Group CEO: Group Well Positioned to Navigate Current Complex Environment

2026. g. 10. apr. 16:11 UTC

Peļņas

Partners Group: Traditional Programs Contributed $3.3B

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group: $5B of New Commitments Came From Bespoke Solutions

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group: That Is Across All Private Markets Asset Classes and Client Strategies

2026. g. 10. apr. 16:10 UTC

Peļņas

Partners Group 1Q New Client Demand $8.3B

2026. g. 10. apr. 16:09 UTC

Peļņas

Partners Group Continued to See Positive Fundraising Momentum in 1Q

2026. g. 10. apr. 15:54 UTC

Iegādes, apvienošanās, pārņemšana

Plenitude Completes Acquisition of Acea Energia

2026. g. 10. apr. 15:38 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Simulations Plus Inc Prognoze

Cenas mērķis

By TipRanks

80.91% augšup

Prognoze 12 mēnešiem

Vidējais 23.5 USD  80.91%

Augstākais 31 USD

Zemākais 16 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Simulations Plus Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt

4 ratings

2

Pirkt

2

Turēt

0

Pārdot

Noskaņojums

By Acuity

150 / 348 Rangs Veselības aprūpe

Ziņu noskaņojums

Liecība "Buļļu" tendencei

Volatilitāte

Zem vidējā

Ziņu apjoms (RCV)

Virs vidējā

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Simulations Plus Inc

Simulations Plus, Inc. develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through Software and Services segments. It also offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products. In addition, the company provides products based on mechanistic and mathematical models, such as DILIsym, NAFLDsym, ILDsym, IPFsym, RENAsym, MITOsym, and OBESITYsym products. Further, it offers Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor for chemistry-based computer program that takes molecular structures as inputs and predicts their properties; and MedChem Designer, as well as MonolixSuite products for modeling and simulation that allows for population analyses, rapid clinical trial data analyses, and regulatory submissions. Additionally, the company provides clinical-pharmacology-based consulting services, which includes population pharmacokinetic and pharmacodynamic modeling, exposure-response analyses, clinical trial simulations, data programming, and technical writing services in support of regulatory submissions; and early drug discovery services. Furthermore, it offers creative and insightful consulting services to support its quantitative systems pharmacology and other modeling systems. The company serves pharmaceutical, biotechnology, agrochemical, cosmetics, and food industry companies, as well as academic and regulatory agencies. Simulations Plus, Inc. was incorporated in 1996 and is headquartered in Lancaster, California.
help-icon Live chat